Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease

Deng Ho Yang, Chuan Chou Tu, Shou Cheng Wang, Cheng Chung Wei, Ya Wen Cheng

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Anti-cyclic citrullinated peptide (anti-CCP) antibody is highly specific for diagnosing rheumatoid arthritis (RA). Cigarette smoking is a lifestyle and environmental factor associated with anti-CCP production and is strongly associated with chronic obstructive pulmonary disease (COPD). This study assessed levels of anti-CCP antibodies and rheumatoid factor (RF) among patients with RA and COPD. The study sample comprised 63 patients with RA and 70 patients with COPD, all of whom underwent assessment of anti-CCP antibody and RF levels. Testing revealed that 54.2 % of RA patients and 0 % of COPD patients were positive for anti-CCP antibodies. Additionally, 82.5 % of RA patients and 42 % of COPD patients were positive for RF. Among RA patients, levels of anti-CCP antibodies were higher among smokers than among nonsmokers (242.7 ± 128.3 vs. 68.1 ± 112.1, P <0.001). COPD patients had low titers of RF but were negative for anti-CCP antibodies. The presence of anti-CCP antibodies was a reliable serologic marker in RA diagnosis and was associated with cigarette smoking.

Original languageEnglish
Pages (from-to)971-977
Number of pages7
JournalRheumatology International
Volume34
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Chronic Obstructive Pulmonary Disease
Rheumatoid Arthritis
Antibodies
Rheumatoid Factor
Smoking
cyclic citrullinated peptide
Life Style

Keywords

  • Anti-CCP antibody
  • Chronic pulmonary obstructive disease
  • Rheumatoid arthritis
  • Rheumatoid factor

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease. / Yang, Deng Ho; Tu, Chuan Chou; Wang, Shou Cheng; Wei, Cheng Chung; Cheng, Ya Wen.

In: Rheumatology International, Vol. 34, No. 7, 2014, p. 971-977.

Research output: Contribution to journalArticle

Yang, Deng Ho ; Tu, Chuan Chou ; Wang, Shou Cheng ; Wei, Cheng Chung ; Cheng, Ya Wen. / Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease. In: Rheumatology International. 2014 ; Vol. 34, No. 7. pp. 971-977.
@article{cbb698471c22484eb586e82ed4a5c133,
title = "Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease",
abstract = "Anti-cyclic citrullinated peptide (anti-CCP) antibody is highly specific for diagnosing rheumatoid arthritis (RA). Cigarette smoking is a lifestyle and environmental factor associated with anti-CCP production and is strongly associated with chronic obstructive pulmonary disease (COPD). This study assessed levels of anti-CCP antibodies and rheumatoid factor (RF) among patients with RA and COPD. The study sample comprised 63 patients with RA and 70 patients with COPD, all of whom underwent assessment of anti-CCP antibody and RF levels. Testing revealed that 54.2 {\%} of RA patients and 0 {\%} of COPD patients were positive for anti-CCP antibodies. Additionally, 82.5 {\%} of RA patients and 42 {\%} of COPD patients were positive for RF. Among RA patients, levels of anti-CCP antibodies were higher among smokers than among nonsmokers (242.7 ± 128.3 vs. 68.1 ± 112.1, P <0.001). COPD patients had low titers of RF but were negative for anti-CCP antibodies. The presence of anti-CCP antibodies was a reliable serologic marker in RA diagnosis and was associated with cigarette smoking.",
keywords = "Anti-CCP antibody, Chronic pulmonary obstructive disease, Rheumatoid arthritis, Rheumatoid factor",
author = "Yang, {Deng Ho} and Tu, {Chuan Chou} and Wang, {Shou Cheng} and Wei, {Cheng Chung} and Cheng, {Ya Wen}",
year = "2014",
doi = "10.1007/s00296-013-2926-6",
language = "English",
volume = "34",
pages = "971--977",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease

AU - Yang, Deng Ho

AU - Tu, Chuan Chou

AU - Wang, Shou Cheng

AU - Wei, Cheng Chung

AU - Cheng, Ya Wen

PY - 2014

Y1 - 2014

N2 - Anti-cyclic citrullinated peptide (anti-CCP) antibody is highly specific for diagnosing rheumatoid arthritis (RA). Cigarette smoking is a lifestyle and environmental factor associated with anti-CCP production and is strongly associated with chronic obstructive pulmonary disease (COPD). This study assessed levels of anti-CCP antibodies and rheumatoid factor (RF) among patients with RA and COPD. The study sample comprised 63 patients with RA and 70 patients with COPD, all of whom underwent assessment of anti-CCP antibody and RF levels. Testing revealed that 54.2 % of RA patients and 0 % of COPD patients were positive for anti-CCP antibodies. Additionally, 82.5 % of RA patients and 42 % of COPD patients were positive for RF. Among RA patients, levels of anti-CCP antibodies were higher among smokers than among nonsmokers (242.7 ± 128.3 vs. 68.1 ± 112.1, P <0.001). COPD patients had low titers of RF but were negative for anti-CCP antibodies. The presence of anti-CCP antibodies was a reliable serologic marker in RA diagnosis and was associated with cigarette smoking.

AB - Anti-cyclic citrullinated peptide (anti-CCP) antibody is highly specific for diagnosing rheumatoid arthritis (RA). Cigarette smoking is a lifestyle and environmental factor associated with anti-CCP production and is strongly associated with chronic obstructive pulmonary disease (COPD). This study assessed levels of anti-CCP antibodies and rheumatoid factor (RF) among patients with RA and COPD. The study sample comprised 63 patients with RA and 70 patients with COPD, all of whom underwent assessment of anti-CCP antibody and RF levels. Testing revealed that 54.2 % of RA patients and 0 % of COPD patients were positive for anti-CCP antibodies. Additionally, 82.5 % of RA patients and 42 % of COPD patients were positive for RF. Among RA patients, levels of anti-CCP antibodies were higher among smokers than among nonsmokers (242.7 ± 128.3 vs. 68.1 ± 112.1, P <0.001). COPD patients had low titers of RF but were negative for anti-CCP antibodies. The presence of anti-CCP antibodies was a reliable serologic marker in RA diagnosis and was associated with cigarette smoking.

KW - Anti-CCP antibody

KW - Chronic pulmonary obstructive disease

KW - Rheumatoid arthritis

KW - Rheumatoid factor

UR - http://www.scopus.com/inward/record.url?scp=84903273602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903273602&partnerID=8YFLogxK

U2 - 10.1007/s00296-013-2926-6

DO - 10.1007/s00296-013-2926-6

M3 - Article

C2 - 24366391

AN - SCOPUS:84903273602

VL - 34

SP - 971

EP - 977

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 7

ER -